Evidence map›Paper›PMID 32945366›Full record

ArticleInternational journal of molecular medicine2020

A comprehensive analysis of RHOA mutation positive and negative angioimmunoblastic T-cell lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis.

Alexandra Butzmann, Kaushik Sridhar, Diwash Jangam, Jyoti Kumar, Malaya Kumar Sahoo, Nahid Shahmarvand, Roger Warnke, Elumalai Rangasamy, Benjamin Alan Pinsky, Robert Shigeo Ohgami

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Metabolic determinants of tumour initiation.Nature reviews. Endocrinology · 2023
    Review
  5. Frontiers in oncology · 2023
    Article
  6. Review
  7. Oncoimmunology · 2022
    Article
  8. Review
  9. Mutations inFrontiers in oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Alexandra ButzmannDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Kaushik SridharDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Diwash JangamDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Jyoti KumarDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Malaya Kumar SahooDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Nahid ShahmarvandDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Roger WarnkeDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Elumalai RangasamyAgilent Technologies, Santa Clara, CA 95051, USA.
Benjamin Alan PinskyDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Robert Shigeo OhgamiDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Stanford University · USAgilent Technologies (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angioimmunoblastic T‑cell lymphoma (AITL) is a uniquely aggressive mature T‑cell neoplasm. In recent years, recurrent genetic mutations in ras homolog family member A (RHOA), tet methylcytosine dioxygenase 2 (TET2), DNA methyltransferase 3 alpha (DNMT3A) and isocitrate dehydrogenase [NADP(+)] 2 (IDH2) have been identified as associated with AITL. However, a deep molecular study assessing both DNA mutations and RNA expression profile combined with digital image analysis is lacking. The present study aimed to evaluate the significance of molecular and morphologic features by high resolution digital image analysis in several cases of AITL. To do so, a total of 18 separate tissues from 10 patients with AITL were collected and analyzed. The results identified recurrent mutations in RHOA, TET2, DNMT3A, and IDH2, and demonstrated increased DNA mutations in coding, promoter and CCCTC binding factor (CTCF) binding sites in RHOA mutated AITLs vs. RHOA non‑mutated cases, as well as increased overall survival in RHOA mutated patients. In addition, single cell computational digital image analysis morphologically characterized RHOA mutated AITL cells as distinct from cells from RHOA mutation negative patients. Computational analysis of single cell morphological parameters revealed that RHOA mutated cells have decreased eccentricity (more circular) compared with RHOA non‑mutated AITL cells. In conclusion, the results from the present study expand our understanding of AITL and demonstrate that there are specific cell biological and morphological manifestations of RHOA mutations in cases of AITL.

Indexed as

AdultAgedBiomarkers, TumorFemaleHigh-Throughput Nucleotide SequencingHumansImmunoblastic LymphadenopathyIsocitrate DehydrogenaseLymphoma, T-CellMaleMiddle AgedMutationrhoA GTP-Binding ProteinBiomarkers, TumorIsocitrate DehydrogenaserhoA GTP-Binding ProteinRHOA protein, human

Identifiers

PMID32945366
PMCPMC7447311
OpenAlexW3045633118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.